compounded semaglutide no longer available FDA Warns on Certain Forms

Landmark trials show semaglutide (Wegovy) produces 10-15% body weight reduction over 68 weeks, while tirzepatide achieves 20-22% reduction by targeting dual GLP-1 and GIP pathways

This dual mechanism produces even stronger appetite suppression and weight loss results in clinical trials

Like many people struggling with weight loss, I wanted something that seemed newer and more effective than traditional medications

Retatrutide is an investigational drug that has not been approved by the FDA or any other regulatory agency

It is more common in children and young adults, while type 2 is more prevalent in people over 40

Close to I4 and Sandlake Road